

# Omnipod DASH® Insulin Management System

Simplify  
Insulin  
Delivery

**Marcus B.**  
PODDER™ SINCE 2017

Information for Health  
Care Professionals




# The Omnipod DASH® Insulin Management System may simplify the burden of multiple daily injections (MDI)



OMNIPOD: 1

vs.



MDI: 14

Average number of injections required every 3 days  
(MDI: ~4.5 per day)

## Why people choose to switch from MDI to the Omnipod® System<sup>1</sup>

- 1 Want better blood glucose control
- 2 Want more freedom
- 3 Tired of multiple daily injections



Kelly R.  
Podder since 2019

✓ FREEDOM ✓ COMFORT ✓ FLEXIBILITY

## Why people choose the Omnipod® System over other insulin pumps<sup>1</sup>

- 1 Tubeless design
- 2 Ease of use
- 3 Waterproof\*
- 4 Trust it to manage their diabetes<sup>2</sup>

\*The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM is not waterproof.

1. Source : Spring 2018 Customer satisfaction survey 2018 - Orchard Market research ,data on File . Completed on Prior generation not available in Australia
2. Polonsky WH et al. Impact of Omnipod® Insulin management System on Quality of Life: A Survey of Current Users. Diabetes Technology & Therapeutics. 2016;18(10):664-670. This study was completed on a prior generation of the Omnipod® Insulin Management System.



# The Omnipod DASH® System provides flexibility and freedom for your patients and practice

- > Presets on Personal Diabetes Manager (PDM) for more personalised insulin delivery
- > An easy upload to Glooko® data management system



**EASY TO USE**

The Pod and the Omnipod DASH® Personal Diabetes Manager (PDM) communicate via Bluetooth® wireless technology\* to deliver continuous insulin delivery

**SITE ROTATION TRACKER**

Place Pod almost anywhere your patient would give themselves insulin

**NO SIPHON EFFECT<sup>3</sup>**

No tubing minimises pump flow variability

**UP TO 3-DAY\*\*WEAR**

Lightweight, disposable Pod; holds up to 200 units of insulin

**NO NEED TO DISCONNECT**

Waterproof Pod\*\*\*

**AUTO-CANNULA INSERTION**

Consistent, hands-free cannula-insertion

Screen image is an example, for illustrative purposes only.

\*At start up, the PDM and Pod should be adjacent and touching, either in or out of tray to ensure proper communication during priming. Within 1.5 metres during normal operation.

\*\*Up to 72 hours of continuous insulin delivery.

\*\*\*The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM is not waterproof.

3. Zisser HC. Siphon Effects on Continuous Subcutaneous Insulin Infusion Pump Delivery Performance. J Diabetes Science and Technology. 2010;4(1):98-103. This study was completed on a prior generation of the Omnipod® Insulin Management System.

# Just three steps\* ensures it's easy to start insulin delivery with the Omnipod DASH® System

The simple design of the Omnipod DASH® System means it requires just three steps to start insulin delivery

## Step 1. Fill\*

Fill the Pod with insulin (from 85 to 200 units of rapid-acting U-100 insulin, e.g. NovoRapid®, Humalog®, Fiasp® or Apidra®). The Pod primes itself and performs a series of safety checks.

\*At start-up, the Pod and PDM must be adjacent and touching



## Step 2. Apply

Apply Pod to the prepared infusion site and run finger around the adhesive to ensure application.



## Step 3. Pump

Press 'Start' on the PDM to activate virtually pain-free, automated insertion of the soft cannula and begin insulin delivery.



Screen image is an example, for illustrative purposes only.




\*Refer to the Omnipod DASH® Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions



# Automated cannula insertion, personalised insulin delivery and more freedom to live life

Omnipod DASH® System provides up to 3 day non-stop\* insulin delivery - no need to disconnect or disrupt insulin delivery.


- > No visible insertion needle. With the press of a button on the PDM, the cannula is inserted in just under 0.005 seconds.
- > Wear almost anywhere insulin would be injected
- > No tubes
- > Freedom to move, play, exercise, swim, sleep, be intimate and live life




**Kelly R.**  
Podder since 2019

# With the Omnipod DASH® System, quality of life may be improved for your patients

US CUSTOMER SATISFACTION SURVEY<sup>7</sup>



PERCENTAGE OF PATIENTS REPORTING IMPROVED QUALITY OF LIFE IN A US SURVEY<sup>8</sup>




7. Source: Spring 2018 Customer Satisfaction Survey – Orchard Hill Market Research. Data on File. This study was completed on a prior generation of the Omnipod® Insulin Management System.

8. Polonsky WH, Hessler D, Layne JE, Zisser H. Impact of the Omnipod® Insulin Management System on Quality of Life: A Survey of Current Users. Diabetes Technology & Therapeutics. 2016;18(10):664-670. This study was completed on a prior generation of the Omnipod® Products. The Omnipod® System is not available in Australia

# With no tubing, the Omnipod DASH® System ensures there is no disruption of basal insulin


The Omnipod DASH® System is applied directly to the body and there is no reason for patients to disconnect. Three days non-stop\* insulin delivery may reduce the sustained rise in blood glucose observed when tubed insulin pumps are disconnected.<sup>9</sup>

## MEASUREMENT OF THE IMPACT OF SHORT-TERM INFUSION SET DISCONNECTS ON GLUCOSE LEVELS<sup>9</sup>



A prospective, open-label study, published in Diabetes Care, measured the impact of short-term infusion set disconnects on glucose levels. The conclusion: A "30-minute interruption of basal insulin infusion resulted in significant glucose elevation; ~1 mg/dL for each minute basal insulin infusion was interrupted."<sup>9</sup> ( $P < 0.001$ )

A pump's positioning in relation to the infusion site can impact the expected basal delivery of insulin by up to 25% (1 u/h rate).<sup>10</sup> As the Omnipod DASH® System is tubeless, there is never a height differential between reservoir and infusion site reducing potential variation in basal insulin delivery.<sup>10</sup>



\*Up to 72 hours of continuous insulin delivery

9. Zisser HC. Quantifying the impact of a short interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care. 2008;31:238-239. This study was completed on a prior generation of the Omnipod® Insulin Management System. 10. Zisser HC. Siphon Effects on Continuous Subcutaneous Insulin Infusion Pump Delivery Performance. Results shown from Lab study. J Diabetes Science and Technology. 2010;4(1):98-103. This study was completed on a prior generation of the Omnipod® Insulin Management System. The Omnipod System is not available in Australia.



# Omnipod® Support Programme

The Omnipod® Support Programme is available to make your patient's transition to the Omnipod DASH® System as simple as possible. Omnipod® Australia offers a range of value added services to help you and your patient make the most of what the Omnipod DASH® System has to offer.

## > Pod Experience Kit

A free, non-functioning sample Pod for your patients that want to try the Pod

## > Omnipod DASH® System Training

Our local clinical sales managers are available to support you in getting your patients trained and started on the Omnipod DASH® System

## > Educational and Training Resources

How-to videos, resource guides, lots of educational and training support for you and your patients, always available on [www.omnipod.com/eu-au](http://www.omnipod.com/eu-au)

## > Reordering consumables


For guidance on how your patient can reorder Pods and other consumable items, please contact your local Omnipod® Customer Care Team

## > Insulet Pod Disposal Programme

Provides Podders™ with an alternative way to dispose of used Pods. Please refer your Podders to their local Omnipod® Sales Team for more information

## > Insulet Partnering with Glooko®

Access for you and your patient to all of their diabetes information in one easy-to-use platform. They can review their diabetes patterns on their smartphone or personal computer, understand the cause-and-effect relationship of their activities on your blood glucose, and easily share their diabetes data with you



Beckham P.  
PODDER™ SINCE 2019

For more information please visit [OMNIPOD.COM/EU-AU](http://OMNIPOD.COM/EU-AU) or give your local Omnipod® Customer Care Team a call.

# Omnipod® Customer Care Team

Our goal is to make life easier for you and your patients.  
You can be confident knowing we're with you every step of the way.

The Omnipod® Customer Care Team is available 24 hours a day, 7 days a week to assist you or your patient with any questions or queries about the Omnipod DASH® System.

Phone

1800 954 074

Calling from  
International

+61 272 084352

Email:

Omnipod-aus@insulet.com

[VISIT OMNIPOD.COM/EU-AU](https://www.omnipod.com/eu-au)

## Continual innovation

At Insulet, we're constantly improving our technology keeping you in mind.  
When we have something new to share, you'll be the first to know.

## Important Safety Information:

The Omnipod DASH® Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. The Omnipod® System and Omnipod DASH® System has been tested and found to be safe for use with the following U-100 insulin: Novolog®/NovoRapid®, Humalog®, Fiasp®, Admelog® or Apidra®. Refer to the Omnipod® Insulin Management System User Guide or the Omnipod DASH® Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.

\*Calls may be monitored and recorded for quality monitoring purposes.  
Calls to 1800 numbers are free from local landlines, but other networks may charge for these calls.

[OMNIPOD.COM/EU-AU](https://omnipod.com/eu-au) >



©2021 Insulet Corporation. Omnipod, the Omnipod logo, DASH, the DASH logo and Podder are trademarks or registered trademarks of Insulet Corporation in the USA and other various jurisdictions. The Bluetooth® word marks and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license. Glooko is a trademark of Glooko, Inc. and used with permission. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation. All rights reserved. INS-ODS-07-2021-00004 v1.0

